stockrowBioNTech SE Sponsored ADR
BNTX Healthcare Biotechnology
BioNTech SE Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 9.07% from fiscal 2024.
- Revenue
- −16.4%
- EPS
- +708.4%
- Free cash flow
- −123.8%
- Total debt
- +44.4%
Quarter to September 2026, against a year earlier
Follow BNTX
Alert me
BioNTech SE Sponsored ADR (BNTX) Return on assets
BioNTech SE Sponsored ADR's return on assets over the twelve months to 30 September 2026 was −7.22%, down 2.0 percentage points from fiscal 2025 (−5.22%). Over the past ten years it has ranged from −24.1% (fiscal 2019) to 113.9% (fiscal 2021); the current reading is higher than 44% of that period. That is above the Biotechnology industry median of −45.6% and above the Healthcare sector median of −29.3%.
Return on assets, annual
Embed this chart
Annual newest first
| Period | Return on assets | Change (points) |
|---|---|---|
| FY2025 | −5.22% | (2.30) |
| FY2024 | −2.92% | (6.99) |
| FY2023 | 4.07% | (41.89) |
| FY2022 | 46.0% | (67.96) |
| FY2021 | 113.9% | 112.94 |
| FY2020 | 0.98% | 25.08 |
| FY2019 | −24.1% | (9.39) |
| FY2018 | −14.7% | 1.51 |
| FY2017 | −16.2% | — |
Against its own ten years
Return on assets against peers
| Company | Return on assets |
|---|---|
| ASND Ascendis Pharma A/S compare | 44.3% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 41.3% |
| EXEL Exelixis, Inc. compare | 33.2% |
| GMAB Genmab A/S Sponsored ADR compare | 8.30% |
| INCY Incyte Corporation compare | 5.92% |
| ROIV Roivant Sciences Ltd. compare | −5.15% |
| BNTX BioNTech SE Sponsored ADR | −7.22% |
| INSM Insmed, Inc. compare | −26.4% |
| BBIO BridgeBio Pharma, Inc. compare | −37.5% |
| Biotechnology industry median | −45.6% |
| Healthcare sector median | −29.3% |
| Market median | 0.00% |
What Return on assets is
ROA tells an investor how much profit a company earns for shareholders from the assets it uses to run its business.
Annual: Net Income Allotted to Shareholders ÷ Average Assets; TTM: Net Income Allotted to Shareholders ÷ Average Assets (latest quarter)
More on BNTX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement